Record growth, guidance beat track solid—defense upside requires years
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Buy
confidence 8/10
Grade A
Hit FY27 interim targets, confident on beat, clear on near-term. No prior misses flagged.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Q2 delivered 69% YoY growth and 80% PAT growth with margin expansion (29% EBITDA), on track to beat ₹14,000 Cr FY27 guidance. Large order book (₹20,178 Cr) and structural defense opportunity (Pinaka, Bhargavastra) underpin long-term. Key risk: major defense programs are 2–3 years to commercialization; external headwinds (commodity, supply chain) could compress margins.
₹3518.9 Cr
Revenue · +69% YoY₹650 Cr
Reported PAT · +79.7% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Domestic explosives stand at 29%, up from 27%
METDomestic mix 29% vs 27% prior year—exact call figures
International explosives 43%, down from 46% YoY
METInternational 43% vs 46% prior year—call exact
Defense revenue 29% of mix, up from 24%
METDefense ₹1,002 Cr = 29% of ₹3,519 Cr Q2; prior year 24%
Will surpass ₹14,000 Cr FY27 guidance
METH1 ₹7,187 Cr on track; Q2 monsoon-impacted (-4.1% QoQ), H2 expected stronger; pace supports beat
Margins to reach 28–30%, expecting ~29% FY27
METH1 EBITDA margin 28.45%, Q2 at 29.02%; full-year ~29% is realistic vs 28% prior guidance
Earnings quality
What changed since the last call
Defense revenue mix expanded
UpgradeDefense now 29% of revenue (₹1,002 Cr Q2) vs 24% prior year; tracking to ₹4,500 Cr FY27 on path
FY27 margin outlook raised modestly
UpgradeExpecting 28–30% (avg ~29%) vs prior 28% guidance; H1 EBITDA margin 28.45%, Q2 at 29.02%
International 43%, domestic recovered
NeutralInternational 43% (vs 46% prior, -300 bps) but domestic 29% (vs 27%, +200 bps); domestic demand pickup compensated
No FY28/29 guidance quantified
WithdrawnManagement explicitly said will provide multi-year targets only after FY27 close; deferred clarity
The Q&A
Analysts probed defense timelines, Omnia integration, MALE UAV status, margin sustainability, capacity constraints. Management candid on trials (Pinaka/Bhargavastra 2–3 years to commercialization), deferred Omnia updates, acknowledged MALE UAV news drought but stayed confident on execution. Held firm on ₹14,000 Cr beat.
Domestic non-defense growth — Amit Dixit, Goldman Sachs
AnsweredGrowth momentum will be better in H2. Monsoon impact Q2; coal mining demand good. Expect strong domestic growth H2 also. Demand outlook positive.
Pinaka order status — Amit Dixit, Goldman Sachs
AnsweredPinaka order ~₹3,000 Cr expected, negotiation ongoing. Received bid ~1.5 years back. In final negotiation stage now. Order book given best price, expect conclusion very soon.
155mm shells capacity — Amit Anwani, PL Capital
AnsweredEstablishing 155mm facility, set up already. Want to scale up to 155mm vertical. Established counter-drone systems in Indian market, will help break international orders. Pinaka supplies ongoing.
Missile tech/MALE UAV — Vikash Singh, ICICI Securities
AnsweredMissile tech opportunity aligned with Solar's capabilities (energetic materials, propellants, warheads, rocket integration). One of most competent private partners for tactical missile programs. MALE UAV: news dried up; no current procurement impact.
Defense capability gaps — Amit Mahawar, UBS Securities
AnsweredDefense complex; in it 15 years. Always challenging to adopt new technologies. At Solar, integrated large facilities handling all ammunition types. Focusing on developing programs with DRDO. Continuous process finding gaps. Confident should adopt new things, offer smart products.
FY27 guidance beat & margins — Tanmay, Aditya Birla Sun Life
AnsweredWill definitely surpass ₹14,000 Cr FY27 guidance. H1 always weaker, H2 better. Domestic now 27–28%, will deliver more H2. Margins will cross 29% on average. Defense at ₹1,000 Cr Q2, ₹900 Cr prior Q = ₹1,900–₹2,000 Cr H1 total; expect ₹4,500 Cr FY27. Surpass guidance on top line.
Bhargavastra trials timeline — Pinakin, HSBC
AnsweredBhargavastra: like said, internal trials calendar year and field trial also calendar year. Once complete, commercialization starts. Years to reach commercialization stage. Huge demand for such products.
Omnia acquisition clarity — Pinakin, HSBC
PartialOmnia detailed call couple months back, no more updates at this stage. Questions can be answered once acquisition is completed.
155mm shells delivery timelines — Kavish Parekh, 360 ONE Capital
PartialShare at appropriate stage on 155mm program. Total order book defense ~₹18,000 Cr, most from international markets. Will address 155mm program at right time. Variety of products in order book including 155mm products.
Volume growth outlook & capex — Kavish Parekh, 360 ONE Capital
AnsweredCapacity expansion in different parts of country for growing domestic demand, especially housing/infrastructure/coal mining. Industry growth ~6–7%, our volume growth 10–15% range. Will be enhanced by capability & capacity expansion.
Defense/export business outlook — Amit Mahawar, UBS Securities
DodgedThis call is for quarterly/half-yearly results. Will provide full clarity on FY27 results. Cannot give guidance for FY28/29 yet due to uncertainties (geopolitical, supply chain, commodity). Will restrict discussion to Q2 H1 FY27 results.
International order book detail — Tanmay, Aditya Birla Sun Life
PartialSupply to 90+ countries. Inquiries practically from every nation allowed by Government of India. 20,178 Cr order book, defense ~₹17,568 Cr. Getting inquiries & orders from various countries. Cannot disclose details per confidentiality.
Guidance
FY27: ₹14,000 Cr+ (will 'surpass' baseline target)
HighH1 ₹7,187 Cr on pace. Q2 monsoon-impacted (-4.1% QoQ); H2 seasonally stronger. Beat implied by management.
FY27: 28–30% EBITDA margin, expecting ~29% avg
HighH1 EBITDA margin 28.45%, Q2 at 29.02%. Prior target 28%; upside now 28–30%. Defense upside to benefit margins.
Greenfield expansion ongoing; no specific FY27 capex target disclosed
MediumPrior FY27 guidance was ₹2,050 Cr capex. Expansion in domestic capacity (155mm shells facility, ammunition lines) underway.
Risks the call surfaced
Defense program execution
HighPinaka (₹3,000 Cr expected) and Bhargavastra (₹3,000+ Cr) still in trial phase. Commercialization 2–3 years out. RFP conversion uncertain; contract finalization can take years.
Commodity & supply chain
MediumGeopolitical issues, supply chain disruptions, commodity price volatility acknowledged. Could compress EBITDA margins (target 28–30%) if unabated.
International market exposure
MediumInternational explosives 43% of revenue; 90+ countries served but specifics withheld for confidentiality. Exports subject to GOI restrictions. Geopolitical shifts could limit market access.
Domestic market cyclicality
MediumDomestic explosives 29% of revenue; demand tied to coal mining, infrastructure investment. Monsoon impact Q2 evident (-4.1% QoQ). Slowdown could compress H2 growth.
Omnia acquisition
LowOmnia (agri-explosives) acquisition pending approvals. No updates provided; contingent on regulatory/antitrust clearance. Delays could defer accretive revenue.
Management
Score 8/10. Clear on Q2 numbers and segment splits. Candid on defense program timelines (2–3 years to commercialization). Deferred FY28/29 guidance citing uncertainty—prudent, not evasive. Q2 beat FY27 interim targets (revenue ₹3,519 Cr on guidance), margins 29% (vs 28% prior). H1 on pace to beat ₹14,000 Cr FY27. No material misses flagged.
1 · H2 FY27
Seasonal demand recovery (monsoon over), higher revenue expected vs Q2; on track for ₹14,000+ Cr beat
2 · FY28–FY29
Defense program commercialization (Pinaka, Bhargavastra); RFP flow expected post trials
3 · CY2026–2027
Omnia acquisition close (pending approvals); agri-explosives portfolio addition
Key risk: major defense programs are 2–3 years to commercialization; external headwinds (commodity, supply chain) could compress margins.
Defence acceleration and margin expansion into focus as momentum sustains
Solar Industries reports Q2 FY27 on Nov 3. After a record Q1 (+70% revenue, +89% profit), the question is whether the defence-led surge continues. Market watching execution on guidance, Omnia integration setup, and whether margins hold.
What to Expect: The Metric Setup
~₹3,500 Cr
On-plan if Q1 momentum holds. FY27 guide is ₹14,000 Cr; at current run-rate achievable.
~₹600 Cr
Assume Q1's 18.2% net margin; a dip signals working-capital or mix headwind.
~28–30%
Q1 set high bar. Operating leverage from defence, but watch if Omnia integration costs show.
~₹1,050–1,150 Cr
Core growth driver. FY27 target: ₹4,500 Cr (50% growth). Q2 will reveal execution pace.
A strong quarter means Solar holds or exceeds ₹3,600 Cr revenue on ₹18%+ net margins, with defence contributions inline with FY27's 50% growth thesis. A weak quarter would be ₹3,200 Cr or lower, or margin compression below 17%, suggesting either operational delays or inventory build ahead of a seasonal slowdown. The Street is watching whether the company can translate order-book visibility (₹21,350 Cr) into consistent execution across Q2–Q4.
Is the Guidance On Track?
Yes. Q1's ₹3,668 Cr revenue (+70% YoY) and ₹666 Cr profit (+89% YoY) put Solar well ahead of the ₹14,000 Cr FY27 target (₹3,500 Cr quarterly run-rate needed). The company also raised its defence revenue guidance to ₹4,500 Cr for FY27, up from ₹3,000 Cr, underpinned by strong order inflows and India's defence indigenization tailwind. However, the bar is now higher: Q2 must sustain momentum without anomalies (such as lumpy orders pulling forward). The ₹21,350 Cr order book provides high visibility, but Q2–Q4 execution—especially integrating the Omnia acquisition and scaling international operations—will define full-year credibility.
What the Street Says
Since Last Quarter: Filings & Corporate Activity
Oct 27
Nov 3 board meeting to approve Q2 FY27 results — routine, on schedule.
Board Meeting Notice
Oct 15
Solar Explochem acquired Sivasakthi Industrial Explosives for ₹115 Cr. Tuck-in deal to expand explosives capacity and product range in India.
Sivasakthi Acquisition
Sep 29
Solar Explochem Proprietary Limited incorporated in Botswana. Part of broader geopolitical expansion in Africa; international footprint build.
Botswana Subsidiary
Sep 29
Standard SEBI-mandated closure for Q2 results. No unusual insider activity flagged.
Trading Window Closure
Sep 14
Major: Solar SA Investments (subsidiary) to acquire South Africa's Omnia Holdings for $1.355B (₹12,951 Cr). Defence + explosives play; diversification into South African market and SADC region.
Omnia Holdings Acquisition
Aug 13
Record quarter: ₹3,668 Cr revenue (+70% YoY), ₹666 Cr PAT (+89% YoY). Management maintained ₹14,000 Cr FY27 revenue target; hiked defence guidance 50%.
Q1 FY27 Results
The Omnia deal is the headline. At ~₹12,951 Cr (or ~$1.355B), it's a material acquisition—roughly 8–9 months of annualized FY26 revenue—signaling ambition to build a global defence explosives and mining chemicals franchise. The deal is expected to close in H1 FY28, so Q2 results will not reflect Omnia's earnings, but management may discuss integration timelines and synergies. The Sivasakthi tuck-in (₹115 Cr) is routine capacity expansion. The Botswana subsidiary is part of the Africa footprint rollout post-Omnia.
1 · Defence revenue acceleration
Is Q2 defence revenue tracking the ₹4,500 Cr FY27 guidance? Look for the absolute number and YoY/QoQ growth rate. If it's +40–50%, the thesis holds. If it dips below +30%, execution risk rises.
2 · Margin narrative
Can Solar hold ₹18%+ net margins despite Omnia integration costs and raw-material inflation? If PAT margin dips to 16% or below, either working-capital is tightening or there's unannounced headwind. Management commentary on FY27 margin guidance will be critical.
3 · Omnia timeline & synergies
Even though the deal closes in H1 FY28, management will likely discuss expected accretion and cost synergies post-close. A vague or conservative outlook could trigger valuation rerating.
4 · Order book & forward visibility
The June order book was ₹21,350 Cr. Q2 results will show inflows and conversions. Any material slowdown in order inflows would be a yellow flag for FY28 growth.
Solar Industries enters Q2 FY27 as a momentum play on India's defence indigenization and international expansion. Q1 set a high bar (₹3,668 Cr, +70% YoY; ₹666 Cr PAT, +89% YoY), and the Street expects repetition. With a ₹21,350 Cr order book and a raised defence-revenue guidance of ₹4,500 Cr (+50%), the company has visibility. The Omnia acquisition ($1.355B), announced mid-cycle, is a strategic bet on global scale. Q2 will test whether Solar can sustain momentum while managing integration prep and raw-material inflation.
Key numbers to watch: revenue ~₹3,500 Cr (on-plan if momentum holds), PAT ~₹600 Cr (test of margin stability), and defence revenue confirmation of the +50% FY27 thesis. The consensus is bullish (Buy, 9.8% upside), but execution risk is real—especially if the company signals any near-term headwinds or delays in order conversions.
Solar Industries Q2FY27: Consolidated PAT Up 80% YoY to ₹650 Cr as Margins Keep Expanding
PAT +79.73% YoY · revenue +69% · margins expanding
₹3,518.92 Cr
+69% YoY
₹650.04 Cr
+79.73% YoY
18.39%
+1.3pp YoY
₹68.19
Solar Industries' consolidated Q2 FY27 (quarter ended September 30, 2026) PAT rose 79.7% YoY to ₹650.04 Cr (owners' share ₹617.02 Cr) on revenue of ₹3,518.92 Cr, up 69.0% YoY — a clean print with no exceptional items on either side of the comparison, so the growth is fully organic. Sequentially, revenue eased 4.1% and PAT 2.5% from Q1 FY27's ₹3,668.20 Cr / ₹666.37 Cr, a normal give-back after an unusually strong first quarter rather than a change in trend, since the YoY comparison remains the primary signal here.
Q2 FY-2027 vs prior quarters
Profitability kept expanding: operating margin rose to 26.07% from 23.59% a year ago and 25.74% in Q1, while net margin improved to 18.47% from 17.36% YoY and 18.17% QoQ — both climbing for a third straight quarter. That is still roughly 2 percentage points below the ~28% EBITDA margin management guided for FY27 at its May 2026 concall, so the margin story is improving but not yet at the guided level. Consolidated results dwarf the standalone (parent-only) numbers — standalone PAT was ₹320.21 Cr on ₹1,445.63 Cr revenue — underscoring that international and defense subsidiaries, not the India-only explosives business, are driving most of the growth and margin lift.
The stock went into the print at ₹20,366, up 5% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters.
What the summary numbers don't show
EPS (basic/diluted) ₹68.19 vs ₹38.12 YoY and ₹72.11 QoQ
Management provided strong FY27 guidance, targeting INR 14,000 crores in revenue while maintaining current EBITDA margins of approximately 28%. This significant growth is expected to be driven by the defense business, which is projected to cross INR 4,500 crores, and continued momentum in the international segment. A p
— This quarter: met
Against management's FY27 guidance of ₹14,000 Cr revenue (with defense crossing ₹4,500 Cr and ~₹2,050 Cr capex), H1 FY27 consolidated revenue of ₹7,187.12 Cr already covers about 51% of the full-year target, putting the company on track to meet or beat it even as the margin leg lags. No analyst consensus or brokerage preview specific to this quarter could be located, so street expectations are marked unknown rather than assumed; the only available reference is a full-year FY27 analyst consensus of roughly 40% revenue growth and 45% profit growth, which this quarter's YoY prints (69%/80%) are running well ahead of. There was no company press release in the record for this quarter, so there is no management framing to reconcile beyond the FY27 guidance already on file. The Board also used this meeting to approve PW Chartered Accountants LLP as incoming joint statutory auditor, and the quarter carried two acquisitions — the ~$1.35 billion (₹12,951 Cr) agreement for South Africa's Omnia Holdings (September 14, 2026) and the ₹115 Cr Sivasakthi acquisition (October 15, 2026) — that sit outside this quarter's reported financials but point to the next leg of the international scale-up the FY27 guidance anticipated.
W1
Whether H2 FY27 holds the pace needed to clear the ₹14,000 Cr FY27 revenue guidance, given H1's ₹7,187.12 Cr run-rate and this quarter's 4.1% QoQ revenue dip
W2
OPM/NPM trajectory toward management's ~28% EBITDA margin target — currently 26.07% OPM, up from 25.74% in Q1; Q3 will show if the climb continues
W3
Funding and integration progress on the ~$1.35bn Omnia Holdings acquisition and the newly incorporated Botswana subsidiary, both outside H1 financials but relevant to FY28 scale
Consolidated PAT ₹650.04 Cr includes ₹33.02 Cr attributable to non-controlling interests (owners' share ₹617.02 Cr); no exceptional items in current or year-ago quarter so YoY growth is clean; statement is unaudited with limited review by joint auditors Gandhi Rathi & Co. and S R B C & CO LLP.